Torii Pharmaceutical Co.
Torii Nihonbashi Bldg.
7 articles with Torii Pharmaceutical Co.
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.
ALK-Abello A/S’s Partner, Torii Pharmaceutical Co., Gains Approval For Japanese Cedar SLIT-Tablet In Japan
Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex(TM)) in Japan by Partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.
Keryx Biopharmaceuticals Licenses Rights to Japan Tobacco; Torii Pharmaceutical Co. to Pay up to $100 Million
Torii Pharmaceutical Co., Toray Industries, Inc. Start to Co-Promote Hemoperfusion Absorption Column Toraymyxin for Removing Endotoxin
Nippon Chemiphar Co., Ltd. And Torii Pharmaceutical Co. To Terminate Sales Tie-Up For Urinary Alkalizer